THERAPY DOSSIER · th-f33767ab5f58

5Z-7-oxozeaenol (TAK1 inhibitor), with 3-methyladenine used as a separate autophagy inhibitor arm

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29504713 ↗2018Reported benefit

TAK1 mediates excessive autophagy via p38 and ERK in cisplatin-induced acute kidney injury.

MouseChemical/toxinBALB/cMalen = 6 per group for in vivo endpoints; total animal number not…Intraperitoneal5Z-7-oxozeaenol 4 mg/kg; 3-methyladenine 20 mg/kg per day;…First injection 1 hour before cisplatin

Model: Cisplatin-induced acute kidney injury, with cisplatin dissolved in 0.9% saline at 1 mg/mL and given at 20 mg/kg by intraperitoneal injection, and animals killed 72 hours later

TAK1 inhibition lowered serum creatinine and urea nitrogen, reduced tubular damage, decreased LC3II and restored p62, and reduced p38 and ERK phosphorylation after cisplatin.

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…